Long-term efficacy and safety of varenicline for smoking cessation: a systematic review and meta-analysis of randomized controlled trials

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Journal of public health

• Publication date

  2012-01-06

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s10389-011-0476-5
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• School-based programmes for preventing smoking.

  2013cited by this paper
• Effects of varenicline on smoking cessation in patients with mild to moderate COPD: a randomized controlled trial.

  2011influential reference
• Nicotine receptor partial agonists for smoking cessation.

  2011influential reference
• Varenicline Tartrate And Counselling Versus Counselling Alone In A Randomised Controlled Trial For Inpatient Smoking Cessation: 6 Month Interim Results

  2011cited by this paper
• Varenicline for tobacco dependence treatment in recovering alcohol-dependent smokers: an open-label pilot study.

  2011cited by this paper
• Varenicline for Smoking Cessation: Nausea Severity and Variation in Nicotinic Receptor Genes

  2011cited by this paper
• A randomized controlled open comparative trial of varenicline vs nicotine patch in adult smokers: efficacy, safety and withdrawal symptoms (the VN-SEESAW study).

  2010cited by this paper
• Stopping smokeless tobacco with varenicline: randomised double blind placebo controlled trial

  2010cited by this paper
• Efficacy and Safety of Varenicline for Smoking Cessation in Patients With Cardiovascular Disease: A Randomized Trial

  2010influential reference
• A Randomized Trial Of Varenicline For Smoking Cessation In Latin America, Africa And The Middle East

  2010influential reference
• Mood, Side-effects and Smoking Outcomes Among Persons With and Without Probable Lifetime Depression Taking Varenicline

  2009cited by this paper
• The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration

  2009cited by this paper
• Varenicline for smoking cessation: A placebo‐controlled, randomized study

  2009influential reference
• Varenicline and suicidal behaviour: a cohort study based on data from the General Practice Research Database

  2009influential reference
• Cost Effectiveness of Varenicline in Belgium, Compared with Bupropion, Nicotine Replacement Therapy, Brief Counselling and Unaided Smoking Cessation

  2009influential reference
• Cognitive and antismoking effects of varenicline in patients with schizophrenia or schizoaffective disorder.

  2009cited by this paper
• Varenicline augmentation in depressed smokers: an 8-week, open-label study.

  2009cited by this paper
• Mortality attributable to smoking in China.

  2009cited by this paper
• Cost-effectiveness of varenicline compared with nicotine patches for smoking cessation--results from four European countries.

  2009influential reference
• Nicotine replacement therapy for smoking cessation.

  2008cited by this paper
• 中国临床戒烟指南(2007年版,试行本)

  2008cited by this paper
• A clinical practice guideline for treating tobacco use and dependence: 2008 update. A U.S. Public Health Service report.

  2008cited by this paper
• Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial

  2008influential reference
• The efficacy and safety of varenicline for smoking cessation using a flexible dosing strategy in adult smokers : a randomized controlled trial

  2008influential reference
• Varenicline in the routine treatment of tobacco dependence: a pre-post comparison with nicotine replacement therapy and an evaluation in those with mental illness.

  2008cited by this paper
• A double-blind study evaluating the long-term safety of varenicline for smoking cessation*

  2007influential reference
• Antidepressants for smoking cessation.

  2007cited by this paper
• Nicotine receptor partial agonists for smoking cessation (Review)

  2007cited by this paper
• Smoking behavior and related cancers: the role of CYP2A6 polymorphisms.

  2007cited by this paper
• A randomized, placebo-controlled trial of varenicline, a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers.

  2007influential reference
• Efficacy and tolerability of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokers.

  2007influential reference
• Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up.

  2006cited by this paper
• Factors associated with quitting smoking at a tobacco dependence treatment clinic.

  2006cited by this paper
• Varenicline, an α4β2 Nicotinic Acetylcholine Receptor Partial Agonist, vs Sustained-Release Bupropion and Placebo for Smoking Cessation: A Randomized Controlled Trial

  2006influential reference
• Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial.

  2006cited by this paper
• Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial.

  2006influential reference
• Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations

  2006cited by this paper
• Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial.

  2006influential reference
• Efficacy of Varenicline, an 42 Nicotinic Acetylcholine Receptor Partial Agonist, vs Placebo or Sustained-Release Bupropion for Smoking Cessation A Randomized Controlled Trial

  2006influential reference
• Cigarette Smoking Among Adults, United States

  2006cited by this paper
• Smoking Cessation With Varenicline, a Selective α4β2 Nicotinic Receptor Partial Agonist: Results From a 7-Week, Randomized, Placebo- and Bupropion-Controlled Trial With 1-Year Follow-up

  2006cited by this paper
• Self-help interventions for smoking cessation.

  2005cited by this paper
• [Smoking and passive smoking in Chinese, 2002].

  2005cited by this paper
• Controlling the risk of spurious findings from meta‐regression

  2004cited by this paper
• Cigarette smoking among adults--United States, 2002.

  2004cited by this paper
• Predictors of cessation in a cohort of current and former smokers followed over 13 years.

  2004cited by this paper
• Differences in Drug Pharmacokinetics Between East Asians and Caucasians and the Role of Genetic Polymorphisms

  2004cited by this paper
• Measuring inconsistency in meta-analyses

  2003cited by this paper
• Community interventions for reducing smoking among adults.

  2002cited by this paper
• Quantifying heterogeneity in a meta‐analysis

  2002cited by this paper
• Slower metabolism and reduced intake of nicotine from cigarette smoking in Chinese-Americans.

  2002cited by this paper
• Trim and Fill: A Simple Funnel‐Plot–Based Method of Testing and Adjusting for Publication Bias in Meta‐Analysis

  2000influential reference
• Anxiolytics and antidepressants for smoking cessation.

  2000cited by this paper
• Clinical implications of dysregulated cytokine production

  2000cited by this paper
• Emerging tobacco hazards in China

  1999cited by this paper
• Smoking in China: findings of the 1996 National Prevalence Survey.

  1999cited by this paper
• Emerging tobacco hazards in China: 1. Retrospective proportional mortality study of one million deaths

  1998influential reference
• Predictors of smoking cessation in a cohort of adult smokers followed for five years.

  1997cited by this paper
• Bias in meta-analysis detected by a simple, graphical test

  1997cited by this paper
• Assessing the quality of reports of randomized clinical trials: is blinding necessary?

  1996cited by this paper
• Operating characteristics of a rank correlation test for publication bias.

  1994cited by this paper
• Smoking and passive smoking.

  1987cited by this paper
• Smoking and health.

  1970cited by this paper

• GLP-1 receptor agonists for smoking cessation: a narrative review of weight management potential.

  2026cites this paper
• The Effect of Varenicline on Smoking Cessation in Hospitalized Patients: A Systematic Review and Meta-Analysis

  2024cites this paper
• The potential impact of tobacco use on female fertility and pregnancy outcomes: An invited scientific review by EBCOG.

  2023cites this paper
• α4β2* Nicotinic Cholinergic Receptor Target Engagement in Parkinson Disease Gait–Balance Disorders

  2021cites this paper
• alpha4beta2* Nicotinic Cholinergic Receptor Target Engagement in Parkinson Disease

  2020cites this paper
• Varenicline: mode of action, efficacy, safety and accumulated experience salient for clinical populations

  2020cites this paper
• Kjønnsforskjeller i effekter og bivirkninger av legemidler

  2016cites this paper
• Updated information on smoking cessation management

  2016cites this paper
• Risk of neuropsychiatric adverse events associated with varenicline: systematic review and meta-analysis

  2015cites this paper
• Behavioral Counseling and Pharmacotherapy Interventions for Tobacco Cessation in Adults, Including Pregnant Women: A Review of Reviews for the U.S. Preventive Services Task Force

  2015cites this paper
• Pharmaceutical Product Development and Liability with Chantix®: A Teaching Case

  2015cites this paper
• Pharmacy considerations in tobacco cessation for patients suffering from posttraumatic stress disorder

  2013cites this paper